Researchers at Johns Hopkins University School of Medicine have unveiled a groundbreaking compound, designated JH-7742, that significantly slows memory deterioration in early-stage Alzheimer's patients. The two-year Phase III clinical trial involving 1,200 participants demonstrated a 35% reduction in cognitive decline compared to the placebo group.
Dr. Elena Markov, lead researcher on the study, stated that the compound works by targeting amyloid-beta plaques while simultaneously protecting synaptic connections. Unlike previous treatments that focused solely on plaque removal, JH-7742 employs a dual-action mechanism that preserves neural pathways already under stress.
The FDA has granted the drug Breakthrough Therapy Designation, expediting its review process. Pending approval, the treatment could reach patients as early as late 2026. The research team has also noted significantly fewer side effects compared to existing approved therapies, with only 8% of participants reporting mild gastrointestinal discomfort.